- Appoints Nancy J. Wysenski as New Lead Independent Director - - David W. Anstice AO and Wendy L. Dixon, Ph.D. to Retire From Board - - Files Preliminary Proxy Statement and Highlights

Related Keywords

Harvard University , Massachusetts , United States , Boston , Athlone , Westmeath , Ireland , Waltham , Ohio , Cambridge , Cambridgeshire , United Kingdom , Dublin , Alex Denner , Katie Joyce , Emily Peterson Alva , Davida Daglio , Nancyj Wysenski , Catot Laurencin , Brianp Mckeon , Christopher Wright , Wendyl Dixon , Vrije Universiteit , Sandy Coombs , Christopheri Wright , Ironwood Pharmaceuticals Inc , Global Medicines Development , Corporate Governance Committee Of The Board , Nasdaq , Vertex Pharmaceuticals Incorporated , Axcella Health Inc , Professor Of Neurology At Harvard Medical School , Cyclerion Therapeutics Inc , Alkermes , Corporate Governance Committee , Wendy , Harvard Medical School , Aavantibio Inc , Exchange Commission , Biochemical Sciences , New Lead Independent Director , Retire From Board , Preliminary Proxy Statement , Highlights Shareholder Engagement Efforts , Annual General Meeting , Annual Meeting , Investor Relations , New Independent Director , With Significant Neuroscience Expertise , Chief Medical Officer , Cyclerion Therapeutics , Ironwood Pharmaceuticals , Associate Professor , Harvard Medical , Alkerme Board , Richard Pops , Chief Executive Officer , Longer Serving Directors , Board Refreshment , Lead Independent Director , Peterson Alva , Sarissa Capital Management , Chief Investment Officer , Sarissa Capital , Senior Vice President , Chief Development Officer , Axcella Health , Scientific Advisor , Magna Cum Laude , Clinical Investigation , Private Securities Litigation Reform Act , Annual Report , Additional Information , Information Regarding Participants , Current Reports , Initial Statements , Beneficial Ownership , Vertex Pharmaceuticals , Nnounces , Ontinued , Board , Efreshment , Ncluding , Appointment , Christopher , Right , Directors ,